PROGRAM PLANNING COMMITTEE

Gilbert H. Friedell
Thomas R. Hakala
George R. Prout, Jr.
Fred Rapp
Willet F. Whitmore, Jr.

Ex. Officio Members
Olga G. Joly
Robert E. Greenfield, Jr.
Arthur G. Hilgar
David R. Kominz
Leon B. Ellwein

PROGRAM

List of Participants .......................................................... 2737

OPENING SESSION
Chairperson: Gilbert H. Friedell

The Organ Site Programs and the National Cancer Program.
Thomas J. King ................................................................. 2743
Overview of the National Bladder Cancer Project and Conference Objectives.

RUBIN H. FLOCKS MEMORIAL LECTURE
Chairperson: Willet F. Whitmore, Jr.

Rubin H. Flocks: In Memoriam ............................................ 2752
The Curability of Vesical Cancer: Greater Now or Then?
Victor F. Marshall and James P. McCarron, Jr. .................................. 2753

SESSION A

Assessment and Management of Deeply Invasive and Metastatic Lesions
Chairpersons: Willet F. Whitmore, Jr., and Morris J. Wizenberg

Introduction: Assessment and Management of Deeply Invasive and Metastatic Lesions.
Willet F. Whitmore, Jr. .......................................................... 2756
The Role of Irradiation in the Management of Clinical Stage B, (Grades II and III) and Stages B2 and C Bladder Cancer.
William L. Caldwell ............................................................. 2759
The Role of Surgery in the Potentially Curative Treatment of Bladder Cancer.
George R. Prout, Jr. .............................................................. 2764
The Chemotherapy of Advanced Bladder Carcinoma.
Jean B. deKernion ............................................................... 2771
Future Implications of Phase 2 Chemotherapy Trials in Ninety-five Patients with Measurable Advanced Bladder Cancer.
Alan Yagoda ........................................................................ 2775
Current Perspectives on Palliative Therapy in Cancer of the Bladder.
Bruce H. Stewart and Andrew C. Novick ...................................... 2781
The Emotional Problems of Patients with Bladder Cancer.
Raymond N. Miller ................................................................ 2789

2734 CANCER RESEARCH VOL. 37
SESSION B

Recognition of “Early” Bladder Cancer and Premalignant Epithelial Changes

Chairpersons: Gilbert H. Friedell and Ralph J. Veenema

Introduction: Recognition of “Early” Bladder Cancer and Premalignant Epithelial Changes.

Gilbert H. Friedell

Clinical Observations on Sixty-nine Cases of in Situ Carcinoma of the Urinary Bladder.

George M. Farrow, David C. Utz, Charles C. Rife, and Laurence F. Greene

Formal Discussion of “Clinical Observations on Sixty-nine Cases of in Situ Carcinoma of the Urinary Bladder.”

Leopold G. Koss

Current Practice of Urinary Bladder Cytology.

William J. Frable, Lois Paxson, Jo A. Barksdale, and Warren W. Koontz, Jr.

Cytology Automation by Flow Cytometry.

Myron R. Melamed, Zbigniew Darzynkiewicz, Frank Traganos, and Thomas Sharpless

The Pathogenesis of Experimental Bladder Cancer.

George T. Bryan


Jerome B. Jacobs, Masayuki Arai, Samuel M. Cohen, and Gilbert H. Friedell

Discussion of Morphological Markers of Early Neoplastic Change in the Urinary Bladder.

R. Marian Hicks

Some Ultrastructural Aspects of Experimental and Human Carcinoma of the Bladder.

Leopold G. Koss

Comments on “Recognition of ‘Early’ Bladder Cancer and Premalignant Epithelial Changes.”

Ralph J. Veenema

SESSION C

Classification of Tumor and Host

Chairpersons: Thomas R. Hakala and Clair E. Cox

Introduction: Classification of Tumor and Host.

Thomas R. Hakala

Current State of Classification and Staging of Bladder Cancer.

Donald G. Skinner

Malignant Transformation of Urinary Bladder in Humans and in N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide-exposed Fischer Rats: Ultrastructure of the Major Components of the Permeability Barrier.

Frederick B. Merk, Bendicht U. Pauli, Jerome B. Jacobs, Joseph Alroy, Gilbert H. Friedell, and Ronald S. Weinstein

Development of Tissue Culture Procedures for Predicting the Individual Risk of Recurrence in Bladder Cancer.

Joseph Leighton, Nabil Abaza, Ruy Tchao, Kim Geisinger, and John Valentich

Approaches for the Isolation of Biologically Functional Tumor-associated Antigens.

R. A. Reisfeld, G. S. David, S. Ferrone, M. A. Pellegrino, and E. C. Holmes

Cell Surface Changes Associated with Malignant Transformation of Bladder Epithelium in Vitro.

Barry D. Kahan, Lynne P. Rutzky, Allayne V. Kahan, Ryoichi Oyasu, Floyd Wiseman, and Stephen LeGrue

Biochemically Detectable Tumor Markers in Urine of Bladder Cancer Patients.

Charles C. Irving

Immunological Responsiveness in Patients with Bladder Cancer.

John L. Fahey, Stanley Brosman, and Fred Dorey

Some Immunological Considerations Relevant to the Study of Human Bladder Cancer.

Michael A. Bean

Classification of the Bladder Cancer Patient Based on in Vitro Measurements of the Immune Response.

Paul H. Lange, Thomas R. Hakala, and Elwin E. Fraley

SESSION D

Management (Control) of Early Bladder Lesions

Chairpersons: George R. Prout, Jr., and George M. Farrow

Introduction: Management (Control) of Early Bladder Lesions.

George R. Prout, Jr.
A Retrospective Study on the Prognostic Import of Flat Carcinoma in Situ Associated with Papillary, Low-Stage Carcinomas of the Bladder.

Alex Althausen, James J. Daly, and George R. Prout, Jr.  
(This paper has been published in the Journal of Urology, 116: 575-580, November 1976).

Survival following Transurethral Resection of Bladder Carcinoma.

Roger W. Barnes, Arthur L. Dick, Henry L. Hadley, and Oliver L. Johnston 2895

Development of a Strategy for a Longitudinal Study of Patients with Bladder Cancer.

National Bladder Cancer Collaborative Group A 2898

Survival, Initial Assessment, and Subsequent Progress of Patients with Superficial Bladder Cancer in a Prospective Longitudinal Study.

National Bladder Cancer Collaborative Group A 2907

Cytology and Histopathology of Bladder Cancer Cases in a Prospective Longitudinal Study.

National Bladder Cancer Collaborative Group A 2911

The Role of Intravesical Thiotepa in the Management of Superficial Bladder Cancer.

National Bladder Cancer Collaborative Group A 2916

Intravesical and Systemic Chemotherapy of Murine Bladder Cancer.

Mark S. Soloway 2918

Histopathological Evaluation of the Inhibition of Rat Bladder Carcinogenesis by 13-cis-Retinoic Acid.

Robert A. Squire, Michael B. Sporn, Charles C. Brown, Joseph M. Smith, Martin L. Wenk, and Stephen Springer 2930

SESSION E

Cause and Prevention of Bladder Cancer

Chairpersons: Fred Rapp and David F. Paulson

Introduction: Cause and Prevention of Bladder Cancer.

Fred Rapp 2937

The Etiology of Bladder Cancer from the Epidemiological Viewpoint.

Anthony B. Miller 2939

The Importance of Synergy between Weak Carcinogens in the Induction of Bladder Cancer in Experimental Animals and Humans.

R. Marian Hicks and Janina Chowaniec 2943

Chromosome Markers and Progression in Bladder Cancer.

Avery A. Sandberg 2950

Endogenous C-type Viruses in Normal and “Abnormal” Cell Development.

Jay A. Levy 2957

Development and Application of Basic Research Techniques in Bladder Cancer Research.

David F. Paulson, Kenneth R. Stone, Don D. Mickey, Robert A. Bonar, and Heidi Wunderli 2969
Cancer Research

37 (8 Part 2)


| Updated version | Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/37/8_Part_2.citation |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |